Drug Profile
Research programme: histamine H3 receptor antagonists - Pfizer Inc
Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Class Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Hypersomnia; Sleep disorders